Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01443442 · ClinicalTrials.gov registry record · Phase 4
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Phase 4 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT01443442 is a Phase 4 study that has completed, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 23 participants.
The verdict
NCT01443442, a Phase 4 study, has completed, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically, patients manifest symptoms in the spring, summer and fall, when airborne allergens are at their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and burning. This is a randomized clinical study to evaluate the efficacy of Bepreve® (bepotastine besilate 1.5% ophthalmic solution) compared to Alrex® (loteprednol etabonate 0.2%) in the treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years. The study will be a two-week study with four visits. Ocular signs (eye redness( and symptoms (itching) will be monitored as outcome variables.
Interventions
- DRUG Loteprednol etabonate
- DRUG bepotastine besilate, 1.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01443442
The ClinicalTrials.gov registry entry for NCT01443442 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol etabonate is the first listed.
NCT01443442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01443442 about?
NCT01443442 is a clinical study titled "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis". Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically, patients manifest symptoms in the spring, summer and fall, when airborne allergens are at their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust mites or pet dander. Signs ...
What is the current status of trial NCT01443442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2011-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01443442?
The interventions under investigation include: Loteprednol etabonate (DRUG), bepotastine besilate, 1.5% (DRUG).
Who is sponsoring clinical trial NCT01443442?
This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.